⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
23,119
Total Claims
$10.0M
Drug Cost
2,027
Beneficiaries
$4,928
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 18,720 Cardiology providers
+223%
Cost per patient vs peers
$4,928 vs $1,524 avg
Brand vs Generic
100% generic
Brand: 0 claims · $0
Generic: 15,328 claims · $397K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Tafamidis | 108 | $2.8M |
| Rivaroxaban | 1,842 | $1.5M |
| Apixaban | 1,656 | $1.3M |
| Empagliflozin | 1,562 | $1.3M |
| Sacubitril/Valsartan | 793 | $747K |
| Dapagliflozin Propanediol | 690 | $567K |
| Macitentan | 21 | $269K |
| Evolocumab | 161 | $169K |
| Semaglutide | 88 | $133K |
| Dronedarone Hcl | 97 | $103K |
| Ranolazine | 857 | $100K |
| Semaglutide | 68 | $86K |
| Icosapent Ethyl | 124 | $71K |
| Vericiguat | 81 | $71K |
| Evolocumab | 76 | $70K |
Prescribing Profile
Patient Profile
75
Avg Age
56%
Female
2.43
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data